Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of switching from retrovir [zidovudine] to tenofovir [tenofovir disoproxil fumarate] or abacavir in HIV-infected patients (SWAP).

Next Previous
Trial Profile

Efficacy and safety of switching from retrovir [zidovudine] to tenofovir [tenofovir disoproxil fumarate] or abacavir in HIV-infected patients (SWAP).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms SWAP; SWAP-TA

Most Recent Events

  • 16 Mar 2012 Actual end date (5 Nov 2010) added as reported by EudraCT.
  • 16 Nov 2011 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
  • 20 Dec 2010 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top